Ingreso
Nombre:

Contraseña:


¿Perdió su Contraseña?
Regístrese Gratuitamente!
Menú
Siguenos en:
Siguenos en Facebook Siguenos en Twitter

Artículos
RSS

Enviado por Biblio on 21/11/2014 10:04:22 (14 Lecturas)

Ver artículo completo

Even if many of the public at large are ambivalent, public discourse around GM is still highly polarised and the discussion is still seen to be ‘about GM’ – a narrative which seemingly hasn’t changed for 20 years.
On 19 November I had the privilege, on behalf of the Nuffield Council on Bioethics, of giving evidence to the House of Commons Science & Technology Select Committee on ‘GM and the Precautionary Principle’.
- See more at: http://nuffieldbioethics.org/blog/2014/discussing-gm/#sthash.ynkm8Fld.dpuf


Enviado por Biblio on 20/11/2014 10:23:56 (34 Lecturas)

Ver artículo completo

Written by Alannah Kittle on October 23, 2014

Last month the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) was excited to take part in the first-ever White House BRAIN Conference. As a part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, President Obama asked the Bioethics Commission to review the ethical issues associated with neuroscience research. In May, the Commission released Gray Matters: Integrative Approaches for Neuroscience, Ethics, and Society, the first of two volumes the Commission will produce in response to the President’s request. Vol. 2 is slated for release in spring 2015. The Bioethics Commission is pleased to play a key role in ensuring the incorporation of ethical considerations into neuroscience research, but just who are the brains behind those who advise about BRAIN?

- See more at: http://blog.bioethics.gov/2014/10/23/the-brains-behind-the-bioethics-commission-and-why-a-multidisciplinary-approach-is-the-smartest-approach/?utm_source=Presidential+Commission+for+the+Study+of+Bioethical+Issues+List&utm_campaign=51c79d41ac-RSS_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_336f8c07f0-51c79d41ac-78447265#sthash.Lt2F38Bj.dpuf


Enviado por Biblio on 19/11/2014 9:55:25 (29 Lecturas)

Ver artículo completo

The Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) heard this morning from a panel of experts representing the neurotechnology sector and regulatory agencies on the ethical considerations in direct-to-consumer (DTC) sales of neurotechnologies. The Bioethics Commission is reviewing the ethical issues associated with the application of neuroscience research in response to President Obama’s request as part of the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative.

Starting off the conversation, John Reppas, M.D., Ph.D., the Director of Public Policy at the Neurotechnology Industry Organization, discussed the current state of the DTC neurotechnology market. Breaking direct-to-consumer neurotechnologies into two categories, Reppas discussed technologies that measure data and have back-end technologies to analyze data, as well as devices that send artificially generated signals into the brain or body.

“Measurement devices are considered quite safe,” said Reppas. “For this product class, the major real-world concern would center on data privacy and ownership, as well as how that data ends up being presented back to the consumer,” said Reppas.

- See more at: http://blog.bioethics.gov/2014/08/20/direct-to-consumer-neurotechnology-ethical-applications-today-and-tomorrow/?utm_source=Presidential+Commission+for+the+Study+of+Bioethical+Issues+List&utm_campaign=ff8fc31a46-RSS_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_336f8c07f0-ff8fc31a46-78447261#sthash.1OyMXuLe.dpuf


Enviado por Biblio on 18/11/2014 9:59:56 (27 Lecturas)

Ver artículo completo

Who doesn’t feel a wrenching in their heart? The Ebola virus, first recognized in 1978, killed less than 2000 people in its first 35 years and double that number in the past 10 months. According to the World Health Organization 416 health care workers have contracted Ebola and, at least, 233 have died. That is almost 6% of deaths.


Enviado por Biblio on 17/11/2014 10:31:50 (43 Lecturas)

Ver artículo completo

El periódico El País publica hoy un artículo ("Inyección farmacéutica") analizando el caso de la vacuna de la varicela y se adentran en el tema de los conflictos de interés de las sociedades científicas, como ya hiciéramos aquí en el post "Los autores declaran no tener ningún conflicto de interés (risas)". Podríamos hacer algún comentario al respecto, pero este extracto del artículo, conversando con el vicepresidente de la Asociación Española de Vacunología centra de forma magistral el problema que tenemos en relación con los conflictos de interés.
Fernando Moraga Llop, vicepresidente primero de la Asociación Española de Vacunología.
—¿Se siente presionado por la industria?
—En absoluto. Llevo mucho tiempo organizando congresos de vacunas. Nosotros decidimos los temas y los ponentes. Hombre, otra cosa es que yo me dirija a un laboratorio y le proponga que nos aporten la intervención de una persona que pueda explicarnos esto o aquello y ellos me lo indiquen.
—¿Su asociación está financiada en más de un 90% por las compañías?
—No sé si ese porcentaje…
—¿De qué presupuesto anual disponen?
—No lo sé ahora mismo. Tendría que hablar con el tesorero.
—Pero las empresas del sector financian sus actividades…


Enviado por Biblio on 14/11/2014 10:39:26 (57 Lecturas)

Ver artículo completo

Last week Ebola came to the United States, it came on a specialized plane in the form of two medical missionaries. The conversation since has revolved around whether or not bringing them home for treatment was wise and/or just.

First, let’s talk about the risk of Ebola transmission, this seems to be the main concern for those who object to the patients being transferred to the U.S. As a nation we are at far greater risk from travelers not yet showing signs of the disease. The two missionaries are being well isolated and every precaution has been taken to ensure the virus does not escape the containment unit. The risk of contamination, transmission, etc. is very low from these patients. It is certainly not zero, a lie I have heard too many times from the media, but it is extremely low.


Enviado por Biblio on 13/11/2014 9:54:08 (148 Lecturas)

Ver artículo completo


Aun contando con que las intervenciones sanitarias estén hechas con buena voluntad, la buena voluntad puede ser una condición necesaria pero no suficiente para analizar y tomar decisiones complejas, como son la mayoría de las actividades sanitarias.

Si es fácil poner calificativos a los fármacos de bueno, neutral y malo, y todos sabemos que en la escala de valores y preferencias lo mejor es un fármaco bueno, después no hacer nada y después un fármaco malo, con las intervenciones sanitarias sucede lo mismo. Por ejemplo la Formación Continuada buena es mejor que no hacer nada. Pero no hacer nada es mejor que la Formación Continuada mala


Enviado por Biblio on 12/11/2014 10:04:01 (51 Lecturas)

Ver artículo completo

In a darkened lab in the north of England, a research associate is intensely focused on the microscope in front of her. She carefully maneuvers a long glass tube that she uses to manipulate early human embryos.

"It's like microsurgery," says Laura Irving of Newcastle University.


Enviado por Biblio on 11/11/2014 9:37:42 (115 Lecturas)

Ver artículo completo

Marie-France Bureau raises concerns about access to, and the funding and regulation of, assisted reproductive treatments.

Quebec Health Minister Gaétan Barrette is expected to introduce new legislation on in vitro fertilization. The costs of the existing program, established in 2010, have skyrocketed to about $70 million annually. Although allocating public funds to reproductive treatments is hard to justify given the burden of health spending in the overall government budget, rumours indicate that Quebec will keep funding some treatments. The bill is expected to limit coverage to medical infertility through a tax credit mechanism.


Enviado por Biblio on 10/11/2014 10:25:32 (137 Lecturas)

Ver artículo completo

In October 1976, the government of Zaire (now the Democratic Republic of Congo [DRC]) asked what was then the U.S. Center for Disease Control, where we worked, to join an international group of scientists in elucidating and controlling an outbreak of an unusually lethal hemorrhagic fever. Just before we arrived in Zaire, our laboratory had used virologic and immunologic tests to identify the cause as a new filovirus, and we brought electron micrographs of the agent.1 In Zaire, we became, respectively, the chief of surveillance, epidemiology, and control and the scientific director of the International Commission for the Investigation and Control of Ebola Hemorrhagic Fever in Zaire.


(1) 2 3 4 ... 100 »
Bioètica i Debat Ediciones SL